Bristol-Myers Squibb Company (BMY) 66.60 $BMY
Final Glance: Pharmaceuticals companies
AP - 2 hrs 52 mins ago
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 100.43 (+0.13), BAX: 70.38 (+0.33), PFE: 34.93 (+0.04), BMY: 66.60 (-0.21)
Midday Glance: Pharmaceuticals companies
AP - Wed Apr 22, 12:39PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
JNJ: 100.43 (+0.13), BAX: 70.38 (+0.33), PFE: 34.93 (+0.04), BMY: 66.60 (-0.21)
Early Glance: Pharmaceuticals companies
AP - Wed Apr 22, 9:25AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
JNJ: 100.43 (+0.13), BAX: 70.38 (+0.33), PFE: 34.93 (+0.04), BMY: 66.60 (-0.21)
A Discussion Of Amgen's Q1 Results, With Updates On Its Pipeline
DoctoRx - at Seeking Alpha - Wed Apr 22, 8:28AM CDT
PFE: 34.93 (+0.04), AMGN: 169.10 (+0.64), LLY: 72.30 (+0.09), BMY: 66.60 (-0.21), SNY: 51.59 (+0.03), REGN: 472.63 (+9.41), HSP: 87.80 (+0.04), CELG: 115.54 (+0.72)
Is Immuno-Oncology the Best Area of Biotech to Invest in Right Now?
George Budwell, The Motley Fool - Motley Fool - Wed Apr 22, 7:11AM CDT
Biotechnology is rapidly giving rise to ground-breaking new medicines that are dramatically changing the outlook for devastating diseases such as hepatitis C, malaria, and, perhaps most astoundingly, cancer. This innovation boom has gone hand in hand...
AGEN: 6.08 (+0.21), ADXS: 22.18 (+0.10), PFE: 34.93 (+0.04), MRK: 57.69 (+0.03), AZN: 73.35 (+0.65), BMY: 66.60 (-0.21), FPRX: 24.07 (-0.85)
Clopidogrel Bisulfate Market 2015-2020 Research Reviews
PR Newswire - Wed Apr 22, 7:00AM CDT
DeepResearchReports.com have "2015 Market Report on Global Clopidogrel Bisulfate Industry" added to its research database. The report spread across 159 pages and available for ready purchase priced at the single user pdf (USD 2600).
BMY: 66.60 (-0.21)
Healthcare's Health Scanner: Complementary Research on Pfizer, Mylan, Teva Pharmaceutical, Bristol-Myers Squibb, and Merck & Company
PR Newswire - Wed Apr 22, 7:00AM CDT
Editor Note: For more information about this release, please scroll to bottom.
MRK: 57.69 (+0.03), PFE: 34.93 (+0.04), MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15), BMY: 66.60 (-0.21)
Exelixis on Path to Beat Estimates; Analyst Brief Issued by BrokerBank Securities, Inc.
PR Newswire - Wed Apr 22, 6:00AM CDT
Exelixis, Inc. (NASDAQ: EXEL) a San Francisco based biotechnology company is set to announce its latest earnings results on April 30, 2015. With recent revisions of earnings estimates, investors are watching to see this darling continue to perform. Exelixis has appreciated significantly since the start of 2015 and growth is expected to continue. Seeing favorable results on its leading compound from the FDA drives the idea of future growth potential.
MRK: 57.69 (+0.03), BMY: 66.60 (-0.21), EXEL: 3.12 (+0.05)
Seattle Genetics' Adcetris Under Review for New Indication - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 5:07PM CDT
Seattle Genetics, Inc.'s (SGEN) supplemental BLA for Adcetris has been accepted by the FDA for priority review as consolidation therapy in the post-transplant setting.
SGEN: 36.92 (-0.32), SHPG: 253.58 (+3.70), HZNP: 30.96 (+0.10), BMY: 66.60 (-0.21)
Bristol-Myers Announces Positive Data from Opdivo Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 5:05PM CDT
Bristol-Myers (BMY) announced encouraging results from a phase II study Opdivo in combination with Yervoy.
BIIB: 423.57 (+1.46), MRK: 57.69 (+0.03), AVEO: 2.04 (+0.12), BMY: 66.60 (-0.21)
SmarTrend Watching for Potential Pullback in Shares of Bristol-Myers Squibb After 1.44% Gain
Comtex SmarTrend(R) - Tue Apr 21, 4:04PM CDT
Bristol-Myers Squibb (NYSE:BMY) traded in a range yesterday that spanned from a low of $66.09 to a high of $67.53. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $66.26 on volume of 6.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BMY: 66.60 (-0.21)
Pulmonary Embolism Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Apr 21, 2:30PM CDT
The report "Pulmonary Embolism - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Pulmonary Embolism. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/pulmonary-em...eport.html .
BMY: 66.60 (-0.21)
Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Apr 21, 10:31AM CDT
The report "Dermatitis - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Dermatitis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/dermatitis-p...eport.html .
VTAE: 14.04 (+0.02), FOMX: 10.94 (-0.02), PVCT: 0.90 (unch), JNJ: 100.43 (+0.13), DERM: 15.36 (-0.62), ANAC: 66.45 (-0.22), XNCR: 14.63 (-0.16), REGN: 472.63 (+9.41), AQXP: 7.91 (-0.41), BMY: 66.60 (-0.21), GSK: 46.57 (-0.67), VRX.TO: 253.14 (-6.24), CBPO: 99.67 (-0.84), MRK: 57.69 (+0.03), CCXI: 7.86 (-0.02), CLTX: 0.74 (-0.01), CELGZ: 2.87 (+0.04), NVS: 103.45 (-0.62)
Next Resistance Level for Bristol-Myers Squibb (BMY) is $66.79
Comtex SmarTrend(R) - Tue Apr 21, 9:07AM CDT
Shares of Bristol-Myers Squibb (NYSE:BMY) opened today above their pivot of $65.78 and have already reached the first level of resistance at $66.33. Analysts will be watching for a cross of the next upside pivot targets of $66.79 and $67.80.
BMY: 66.60 (-0.21)
Bristol-Myers Squibb Company (BMY) Highlighted As Momo Momentum Stock
at The Street - Tue Apr 21, 8:48AM CDT
Trade-Ideas LLC identified Bristol-Myers Squibb Company (BMY) as a momo momentum candidate
BMY: 66.60 (-0.21)
Healthcare ratings roundup
Seeking Alpha - at Seeking Alpha - Tue Apr 21, 8:42AM CDT
IPXL: 49.58 (-0.40), ROSG: 3.83 (-0.20), BCRX: 10.62 (-0.09), ALGN: 55.94 (-0.21), PAHC: 33.44 (+1.09), BMY: 66.60 (-0.21)
Final Glance: Pharmaceuticals companies
AP - 2 hrs 52 mins ago
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 100.43 (+0.13), BAX: 70.38 (+0.33), PFE: 34.93 (+0.04), BMY: 66.60 (-0.21)
Midday Glance: Pharmaceuticals companies
AP - Wed Apr 22, 12:39PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
JNJ: 100.43 (+0.13), BAX: 70.38 (+0.33), PFE: 34.93 (+0.04), BMY: 66.60 (-0.21)
Early Glance: Pharmaceuticals companies
AP - Wed Apr 22, 9:25AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
JNJ: 100.43 (+0.13), BAX: 70.38 (+0.33), PFE: 34.93 (+0.04), BMY: 66.60 (-0.21)
A Discussion Of Amgen's Q1 Results, With Updates On Its Pipeline
DoctoRx - at Seeking Alpha - Wed Apr 22, 8:28AM CDT
PFE: 34.93 (+0.04), AMGN: 169.10 (+0.64), LLY: 72.30 (+0.09), BMY: 66.60 (-0.21), SNY: 51.59 (+0.03), REGN: 472.63 (+9.41), HSP: 87.80 (+0.04), CELG: 115.54 (+0.72)
Is Immuno-Oncology the Best Area of Biotech to Invest in Right Now?
George Budwell, The Motley Fool - Motley Fool - Wed Apr 22, 7:11AM CDT
Biotechnology is rapidly giving rise to ground-breaking new medicines that are dramatically changing the outlook for devastating diseases such as hepatitis C, malaria, and, perhaps most astoundingly, cancer. This innovation boom has gone hand in hand...
AGEN: 6.08 (+0.21), ADXS: 22.18 (+0.10), PFE: 34.93 (+0.04), MRK: 57.69 (+0.03), AZN: 73.35 (+0.65), BMY: 66.60 (-0.21), FPRX: 24.07 (-0.85)
Clopidogrel Bisulfate Market 2015-2020 Research Reviews
PR Newswire - Wed Apr 22, 7:00AM CDT
DeepResearchReports.com have "2015 Market Report on Global Clopidogrel Bisulfate Industry" added to its research database. The report spread across 159 pages and available for ready purchase priced at the single user pdf (USD 2600).
BMY: 66.60 (-0.21)
Healthcare's Health Scanner: Complementary Research on Pfizer, Mylan, Teva Pharmaceutical, Bristol-Myers Squibb, and Merck & Company
PR Newswire - Wed Apr 22, 7:00AM CDT
Editor Note: For more information about this release, please scroll to bottom.
MRK: 57.69 (+0.03), PFE: 34.93 (+0.04), MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15), BMY: 66.60 (-0.21)
Exelixis on Path to Beat Estimates; Analyst Brief Issued by BrokerBank Securities, Inc.
PR Newswire - Wed Apr 22, 6:00AM CDT
Exelixis, Inc. (NASDAQ: EXEL) a San Francisco based biotechnology company is set to announce its latest earnings results on April 30, 2015. With recent revisions of earnings estimates, investors are watching to see this darling continue to perform. Exelixis has appreciated significantly since the start of 2015 and growth is expected to continue. Seeing favorable results on its leading compound from the FDA drives the idea of future growth potential.
MRK: 57.69 (+0.03), BMY: 66.60 (-0.21), EXEL: 3.12 (+0.05)
Seattle Genetics' Adcetris Under Review for New Indication - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 5:07PM CDT
Seattle Genetics, Inc.'s (SGEN) supplemental BLA for Adcetris has been accepted by the FDA for priority review as consolidation therapy in the post-transplant setting.
SGEN: 36.92 (-0.32), SHPG: 253.58 (+3.70), HZNP: 30.96 (+0.10), BMY: 66.60 (-0.21)
Bristol-Myers Announces Positive Data from Opdivo Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 5:05PM CDT
Bristol-Myers (BMY) announced encouraging results from a phase II study Opdivo in combination with Yervoy.
BIIB: 423.57 (+1.46), MRK: 57.69 (+0.03), AVEO: 2.04 (+0.12), BMY: 66.60 (-0.21)
SmarTrend Watching for Potential Pullback in Shares of Bristol-Myers Squibb After 1.44% Gain
Comtex SmarTrend(R) - Tue Apr 21, 4:04PM CDT
Bristol-Myers Squibb (NYSE:BMY) traded in a range yesterday that spanned from a low of $66.09 to a high of $67.53. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $66.26 on volume of 6.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BMY: 66.60 (-0.21)
Pulmonary Embolism Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Apr 21, 2:30PM CDT
The report "Pulmonary Embolism - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Pulmonary Embolism. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/pulmonary-em...eport.html .
BMY: 66.60 (-0.21)
Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Apr 21, 10:31AM CDT
The report "Dermatitis - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Dermatitis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/dermatitis-p...eport.html .
VTAE: 14.04 (+0.02), FOMX: 10.94 (-0.02), PVCT: 0.90 (unch), JNJ: 100.43 (+0.13), DERM: 15.36 (-0.62), ANAC: 66.45 (-0.22), XNCR: 14.63 (-0.16), REGN: 472.63 (+9.41), AQXP: 7.91 (-0.41), BMY: 66.60 (-0.21), GSK: 46.57 (-0.67), VRX.TO: 253.14 (-6.24), CBPO: 99.67 (-0.84), MRK: 57.69 (+0.03), CCXI: 7.86 (-0.02), CLTX: 0.74 (-0.01), CELGZ: 2.87 (+0.04), NVS: 103.45 (-0.62)
Next Resistance Level for Bristol-Myers Squibb (BMY) is $66.79
Comtex SmarTrend(R) - Tue Apr 21, 9:07AM CDT
Shares of Bristol-Myers Squibb (NYSE:BMY) opened today above their pivot of $65.78 and have already reached the first level of resistance at $66.33. Analysts will be watching for a cross of the next upside pivot targets of $66.79 and $67.80.
BMY: 66.60 (-0.21)
Bristol-Myers Squibb Company (BMY) Highlighted As Momo Momentum Stock
at The Street - Tue Apr 21, 8:48AM CDT
Trade-Ideas LLC identified Bristol-Myers Squibb Company (BMY) as a momo momentum candidate
BMY: 66.60 (-0.21)
Healthcare ratings roundup
Seeking Alpha - at Seeking Alpha - Tue Apr 21, 8:42AM CDT
IPXL: 49.58 (-0.40), ROSG: 3.83 (-0.20), BCRX: 10.62 (-0.09), ALGN: 55.94 (-0.21), PAHC: 33.44 (+1.09), BMY: 66.60 (-0.21)
